| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
University of California Center for Human Nutrition, Los Angeles, California 90095
Dietary intakes of tomatoes and tomato products containing lycopene have been shown to be associated with decreased risk of chronic diseases such as cancer and cardiovascular diseases in numerous studies. Serum and tissue lycopene levels have also been inversely related to the risk of lung and prostate cancers. Lycopene functions as a very potent antioxidant, and this is clearly a major important mechanism of lycopene action. In this regard, lycopene can trap singlet oxygen and reduce mutagenesis in the Ames test. However, evidence is accumulating for other mechanisms as well. Lycopene at physiological concentrations can inhibit human cancer cell growth by interfering with growth factor receptor signaling and cell cycle progression specifically in prostate cancer cells without evidence of toxic effects or apoptosis of cells. Studies using human and animal cells have identified a gene, connexin 43, whose expression is upregulated by lycopene and which allows direct intercellular gap junctional communication (GJC). GJC is deficient in many human tumors and its restoration or upregulation is associated with decreased proliferation. The combination of low concentrations of lycopene with 1,25-dihydroxyvitamin D3 exhibits a synergistic effect on cell proliferation and differentiation and an additive effect on cell cycle progression in the HL-60 promyelocytic leukemia cell line, suggesting some interaction at a nuclear or subcellular level. The combination of lycopene and lutein synergistically interact as antioxidants, and this may relate to specific positioning of different carotenoids in membranes. This review will focus on the growing body of evidence that carotenoids have unexpected biologic effects in experimental systems, some of which may contribute to their cancer preventive properties in models of carcinogenesis. Consideration of solubility in vitro, comparison with doses achieved in humans by dietary means, interactions with other phytochemicals, and other potential mechanisms such as stimulation of xenobiotic metabolism, inhibition of cholesterogenesis, modulation of cyclooxygenase pathways, and inhibition of inflammation will be considered. This review will point out areas for future research where more evidence is needed on the effects of lycopene on the etiology of chronic disease.
Key Words: lycopene • carotenoids, tomato products • cancer prevention
This article has been cited by other articles:
|
|
 |
|
  Y. L. Kim, D. R. Jacobs Jr., M. D. Gross, R. C. Bergan, P. H. Gann, K. Liu, and S. M. Gapstur Associations of Serum Carotenoid Levels with Serum Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 Levels in Black Men and White Men Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2781 - 2783. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Napolitano, C. De Pascale, C. Wheeler-Jones, K. M. Botham, and E. Bravo Effects of lycopene on the induction of foam cell formation by modified LDL Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1820 - E1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Key, P. N Appleby, N. E Allen, R. C Travis, A. W Roddam, M. Jenab, L. Egevad, A. Tjonneland, N. F Johnsen, K. Overvad, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study Am. J. Clinical Nutrition, September 1, 2007; 86(3): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chalabi, L. Delort, S. Satih, P. Dechelotte, Y.-J. Bignon, and D. J. Bernard-Gallon Immunohistochemical Expression of RAR{alpha}, RAR{beta}, and Cx43 in Breast Tumor Cell Lines After Treatment With Lycopene and Correlation With RT-QPCR J. Histochem. Cytochem., September 1, 2007; 55(9): 877 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gajic, S. Zaripheh, F. Sun, and J. W. Erdman Jr. Apo-8'-Lycopenal and Apo-12'-Lycopenal Are Metabolic Products of Lycopene in Rat Liver J. Nutr., June 1, 2006; 136(6): 1552 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Kirsh, S. T. Mayne, U. Peters, N. Chatterjee, M. F. Leitzmann, L. B. Dixon, D. A. Urban, E. D. Crawford, and R. B. Hayes A Prospective Study of Lycopene and Tomato Product Intake and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Reboul, P. Borel, C. Mikail, L. Abou, M. Charbonnier, C. Caris-Veyrat, P. Goupy, H. Portugal, D. Lairon, and M.-J. Amiot Enrichment of Tomato Paste with 6% Tomato Peel Increases Lycopene and {beta}-Carotene Bioavailability in Men J. Nutr., April 1, 2005; 135(4): 790 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Hantz, L. F. Young, and K. R. Martin Physiologically Attainable Concentrations of Lycopene Induce Mitochondrial Apoptosis in LNCaP Human Prostate Cancer Cells Experimental Biology and Medicine, March 1, 2005; 230(3): 171 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nkondjock, P. Ghadirian, K. C. Johnson, D. Krewski, and the Canadian Cancer Registries Epidemiology Resear Dietary Intake of Lycopene Is Associated with Reduced Pancreatic Cancer Risk J. Nutr., March 1, 2005; 135(3): 592 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Obermuller-Jevic, E. Olano-Martin, A. M. Corbacho, J. P. Eiserich, A. van der Vliet, G. Valacchi, C. E. Cross, and L. Packer Lycopene Inhibits the Growth of Normal Human Prostate Epithelial Cells in Vitro J. Nutr., November 1, 2003; 133(11): 3356 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Forbes, K. Gillette, and I. Sehgal Lycopene Increases Urokinase Receptor and Fails to Inhibit Growth or Connexin Expression in a Metastatically Passaged Prostate Cancer Cell Line: A Brief Communication Experimental Biology and Medicine, September 1, 2003; 228(8): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
